Abstract
Neurosarcoidosis is an uncommon but potentially serious manifestation of sarcoidosis. While the cranial nerves are most frequently affected, neurosarcoidosis can involve other nervous system tissues including the meninges, brain parenchyma (especially the hypothalamic region), spinal cord, peripheral nerve, and muscle. Diagnosis may be particularly challenging when neurosarcoidosis occurs in isolation. Diagnostic criteria usually include histologic identification of a noncaseating granuloma, supportive laboratory or imaging tests or both, and a compatible clinical course. Treatment has not been subjected to rigorous study, but corticosteroids are typically the first line of therapy and approximately half of patients have substantial benefit. For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and even cranial irradiation. The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as well-designed studies are undertaken.
Keywords: Neurosarcoidosis, sarcoidosis, cranial neuropathy, meningitis, neuroendocrine dysfunction, seizures, peripheral neuropathy, myopathy
Current Neuropharmacology
Title: Neurosarcoidosis
Volume: 9 Issue: 3
Author(s): David Lacomis
Affiliation:
Keywords: Neurosarcoidosis, sarcoidosis, cranial neuropathy, meningitis, neuroendocrine dysfunction, seizures, peripheral neuropathy, myopathy
Abstract: Neurosarcoidosis is an uncommon but potentially serious manifestation of sarcoidosis. While the cranial nerves are most frequently affected, neurosarcoidosis can involve other nervous system tissues including the meninges, brain parenchyma (especially the hypothalamic region), spinal cord, peripheral nerve, and muscle. Diagnosis may be particularly challenging when neurosarcoidosis occurs in isolation. Diagnostic criteria usually include histologic identification of a noncaseating granuloma, supportive laboratory or imaging tests or both, and a compatible clinical course. Treatment has not been subjected to rigorous study, but corticosteroids are typically the first line of therapy and approximately half of patients have substantial benefit. For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and even cranial irradiation. The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as well-designed studies are undertaken.
Export Options
About this article
Cite this article as:
Lacomis David, Neurosarcoidosis, Current Neuropharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157015911796557975
DOI https://dx.doi.org/10.2174/157015911796557975 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis
Current Drug Targets Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Advances in the Treatment of Chronic Granulomatous Disease by Gene Therapy
Current Gene Therapy Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials Temporal Progression of Kainic Acid Induced Changes in Vascular Laminin Expression in Rat Brain with Neuronal and Glial Correlates
Current Neurovascular Research Aminoglycoside-Induced Ototoxicity
Current Pharmaceutical Design Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Complexities of Glucuronidation Affecting In Vitro-In Vivo Extrapolation
Current Drug Metabolism The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme
Current Pharmaceutical Design Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry GABAergic Drugs for the Treatment of Migraine
CNS & Neurological Disorders - Drug Targets An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry